Drug name - Kalydeco

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754224 VERTEX PHARMS Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(4 years from now)

US7495103 VERTEX PHARMS Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

CN102652128A VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Mar, 2015

(7 years ago)

CN101935301A VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN107501099A VERTEX PHARMS Atp-Binding Cassette Transport Protein Modulators
Jun, 2025

(2 years from now)

CN101891680A VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN104788328B VERTEX PHARMS Atp-Binding Cassette Transport Protein Modulators
Jun, 2025

(2 years from now)

CN104788328A VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN103641765A VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101935301B VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN103641765B VERTEX PHARMS Atp-Binding Cassette Transport Proteins Regulating Agent
Jun, 2025

(2 years from now)

CN107501099B VERTEX PHARMS Modulator Of Atp-Binding Cassette Transport Protein
Jun, 2025

(2 years from now)

CN101006076B VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101006076A VERTEX PHARMS Regulator Of Atp-Abc Transport Protein
Jun, 2025

(2 years from now)

CN101891680B VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101384172B VERTEX PHARMS N - (2, 4 - (1, 1 - - Dimethyl Ethyl) -5 - Phenyl] -1, 4 - - Dihydro - -4--- Oxo-Quinoline -3 - Formamide In Solid Form
Dec, 2026

(4 years from now)

CN101384172A VERTEX PHARMS Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

IN282654B VERTEX PHARMS Modulators Of Atpbinding Cassette Transporters
Jun, 2025

(2 years from now)

EP1773816A2 VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jul, 2020

(2 years ago)

EP1773816B1 VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jul, 2020

(2 years ago)

EP2489659B1 VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP3216787A1 VERTEX PHARMS Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2489659A1 VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911A2 VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911A3 VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911B1 VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP3216787B1 VERTEX PHARMS Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP1993360A2 VERTEX PHARMS Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360A4 VERTEX PHARMS Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705A1 VERTEX PHARMS Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705B1 VERTEX PHARMS Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360B1 VERTEX PHARMS Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS Modulators of ATP-binding cassette transporters Jun, 2025

(2 years from now)

US8354427 VERTEX PHARMS Modulators of ATP-binding cassette transporters Jul, 2026

(3 years from now)

US9670163 VERTEX PHARMS Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US8410274 VERTEX PHARMS Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US8324242 VERTEX PHARMS Modulators of ATP-binding cassette transporters Aug, 2027

(4 years from now)

US10646481 VERTEX PHARMS Pharmaceutical composition and administrations thereof Aug, 2029

(6 years from now)

Drugs and Companies using IVACAFTOR ingredient

Treatment: Use of ivacaftor for treating cystic fibrosis in a patient with a mild to moderate cf phenotype with at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data; Method of treating a patient having cystic fibrosis, the patient having a r117h mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide; method of treating cystic fibrosis; Method of treating cystic fibrosis; Method of treating cystic fibrosis; method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET;ORAL Prescription
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754224 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(4 years from now)

US7495103 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

CN102652128A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Mar, 2015

(7 years ago)

CN101935301A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN107501099A VERTEX PHARMS INC Atp-Binding Cassette Transport Protein Modulators
Jun, 2025

(2 years from now)

CN101891680A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN104788328B VERTEX PHARMS INC Atp-Binding Cassette Transport Protein Modulators
Jun, 2025

(2 years from now)

CN104788328A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN103641765A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101935301B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN103641765B VERTEX PHARMS INC Atp-Binding Cassette Transport Proteins Regulating Agent
Jun, 2025

(2 years from now)

CN107501099B VERTEX PHARMS INC Modulator Of Atp-Binding Cassette Transport Protein
Jun, 2025

(2 years from now)

CN101006076B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101006076A VERTEX PHARMS INC Regulator Of Atp-Abc Transport Protein
Jun, 2025

(2 years from now)

CN101891680B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101384172B VERTEX PHARMS INC N - (2, 4 - (1, 1 - - Dimethyl Ethyl) -5 - Phenyl] -1, 4 - - Dihydro - -4--- Oxo-Quinoline -3 - Formamide In Solid Form
Dec, 2026

(4 years from now)

CN101384172A VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

IN282654B VERTEX PHARMS INC Modulators Of Atpbinding Cassette Transporters
Jun, 2025

(2 years from now)

EP1773816A2 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jul, 2020

(2 years ago)

EP1773816B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jul, 2020

(2 years ago)

EP2489659B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP3216787A1 VERTEX PHARMS INC Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2489659A1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911A2 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911A3 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP3216787B1 VERTEX PHARMS INC Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP1993360A2 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360A4 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705A1 VERTEX PHARMS INC Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705B1 VERTEX PHARMS INC Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360B1 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Jun, 2025

(2 years from now)

US8354427 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Jul, 2026

(3 years from now)

US8410274 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US9670163 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US8324242 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Aug, 2027

(4 years from now)

US10646481 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof Aug, 2029

(6 years from now)

US8883206 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof Feb, 2033

(10 years from now)

US10272046 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof Feb, 2033

(10 years from now)

Drugs and Companies using IVACAFTOR ingredient

Treatment: Treatment of a moderate mild clinical phenotype of cf using ivacaftor in a patient age 6 months to <6 years who has one cftr mutation repsonsive to ivacaftor based on clinical and/or in vitro assay data; use of ivacaftor for treating cystic fibrosis in a patient with a mild to moderate cf phenotype with at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data; treatment of a moderate to mild clinical phenotype of cf using ivacaftor in a patient age 4 months to <6 years who has one cftr mutation responsive to ivacaftor based on clinical and/or in vitro assay data; Method of treating cystic fibrosis; treatment of cystic fibrosis using ivacaftor in a patient age 6 months to <6 years who has a r117h mutation in the cftr gene; method of treating a patient having cystic fibrosis, the patient having a r117h mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide; treatment of cystic fibrosis using ivacaftor in a patient age 4 months to <6 years who has a r117h mutation in the cftr gene; Method of treating cystic fibrosis; treatment of cf in a patient age 6 months to < 6 years who has one cftr mutation responsive to ivacaftor based on clinical and/or in vitro assay data using a solid composition comprising amorphous (less than about 30% crystalline) ivacaftor; treatment of cf in a patient age 4 months to <6 years who has one cftr mutation responsive to ivacaftor based on clinical and/or in vitro assay data using a solid composition comprising amorphous (less than about 30% crystalline) ivacaftor; Method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide; method of treating cystic fibrosis; treatment of cystic fibrosis using ivacaftor in a patient age 6 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data; treatment of cystic fibrosis using ivacaftor in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data; Treatment of cf in a patient age 6 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 10272046; treatment of cf in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 10272046

Dosage: GRANULE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG/PACKET GRANULE;ORAL Prescription
50MG/PACKET GRANULE;ORAL Prescription
75MG/PACKET GRANULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.